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Abstract
There is emerging evidence of abnormal expression in human tumors of microRNAs
(miRNAs) which have been assigned oncogenic and/or tumor suppressor functions.
While some miRNAs commonly exhibit altered expression across tumors, more often,
different tumor types express unique patterns of miRNAs, referable to their tissues of
origin. The role of miRNAs in tumorigenesis underscores their value as mechanismbased therapeutic targets in cancer. Similarly, unique patterns of altered microRNA
expression provide fingerprints that may serve as molecular biomarkers for tumor
diagnosis, classification, prognosis of disease-specific outcomes, and prediction of
therapeutic responses.
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Cancer is a leading cause of mortality in the United States, with ~25% of deaths
attributable to neoplasia [1, 2]. Worldwide, cancer-related global mortality follows only
cardiovascular and infectious diseases [3]. In this context of expanded incidence and
growing prevalence, clinical oncology is poised for unprecedented innovation.
Harnessing discoveries in disease pathobiology, increasingly propelled by the
development of high-throughput technologies including genomics, proteomics and
metabolomics, modern cancer biology offers previously unavailable diagnostic and
therapeutic paradigms tailored to meet the needs of individuals and populations [4].
Transforming clinical management is predicated on translation of the new science into
application of advanced markers and targets for personalized cancer prediction,
prevention, diagnosis, and treatment [4-6].
Indeed, the epigenetic, genetic, and post-genetic circuits restricting cell destiny are
increasingly decoded, and their dysfunction linked to lineage-dependence underlying
tumorigenesis [2, 7]. Critical in cell fate specification is post-transcriptional regulation of
gene expression by microRNAs (Fig. 1) [8]. These molecules arise as transcripts from
cognate genes in non-coding regions of chromosomes. MicroRNA undergo nuclear and
cytoplasmic processing [8, 9] producing the targeting core of a multimeric complex
hybridizing with mRNA molecules resulting in their sequestration or degradation, and
thereby define the genes available for lineage commitment [10, 11]. This is the most
recent addition to the hierarchical spectrum of molecular mechanisms defining nuclearcytoplasmic information exchange [12], and forms the interface between transcriptional,
translational, and post-translational regulation [13] Significantly, microRNAs represent a
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regulatory, rather than structural, mechanism that coordinates normal gene expression
and whose dysregulation underlies neoplastic transformation [8, 10, 11].
MicroRNAs and cancer
The essential nature of this novel mechanism indelibly patterning gene expression in
cell lineage specification [8], in the context of the established model of cancer as a
genetic disease in which pathobiology recapitulates cell and tissue ontogeny [14, 15],
naturally implicates microRNAs in neoplastic transformation. In fact, altered microRNA
expression is a defining trait of tumorigenesis [16, 17]. While the expression of some
microRNAs are universally altered in tumors, more often unique patterns of microRNA
expression reflect the lineage-dependence of tumors, referable to their tissues of origin
[16-22]. Similarly, fundamental processes underlying tumorigenesis, including genomic
instability, epigenetic dysregulation, and alterations in expression or function of
regulatory proteins directly alter the complement of microRNAs expressed by cancer
cells [8]. Additionally, microRNAs regulate key components integral to tumor initiation
and progression, including tumor suppressors and oncogenes [8, 17, 23].

Further,

microRNA signatures are a more informative source for classification of tumor taxonomy
than genomic profiling [16]. Moreover, microRNAs can serve as unique targets for
diagnostic imaging in vivo for taxonomic classification of tumors [24]. The emerging role
of microRNAs in neoplasia highlights their potential value as mechanism-based
therapeutic targets and biomarkers for diagnosis, prognosis of disease-specific
outcomes, and prediction of therapeutic responses [25]. While there are numerous
detailed reviews of this field, the purpose of this minireview is to provide, in overview, a
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summary of the potential application of microRNAs as diagnostic and therapeutic
targets in cancer.
MicroRNAs as mechanism-based therapeutic targets in cancer
The case for microRNAs as tumor suppressors and oncogenes reflects their loss or
gain, respectively, as a function of neoplastic transformation, their dysregulation in
different tumors, the relevance of their mRNA targets to mechanisms underlying
tumorigenesis, and their ability to directly alter tumorigenesis in model cells and
organisms (Fig. 2; Table 1) [8, 26, 27]. Typically, microRNAs that serve as oncogenes
are characterized by a gain of expression which inhibits levels of genes encoding tumor
suppressors. Conversely, tumor suppressor microRNAs exhibit a loss of expression in
cancer producing over-expression of transcripts encoded by oncogenes.
MicroRNA Tumor Suppressors (Fig. 2, Table 1)
The best characterized tumor suppressor microRNAs are miR-15a and miR-16-1. B cell
chronic lymphocytic leukemia (CLL) is the most common adult leukemia in developed
countries and universally associated with loss of chromosomal region 13q14 [8, 27, 28].
Within this deletion is a ~30 kb region in which resides miR-15a and miR-16-1, which
are lost in ~70% of patients with CLL [29]. Similarly, loss of chromosomal region 13q14,
including miR-15a and miR-16-1, occurs in prostate cancer, mantle cell lymphoma, and
multiple myeloma [29, 30].

Tumor suppression by miR-15a and miR-16-1, in part,

reflects inhibition of the expression of the anti-apoptotic oncogenic protein Bcl-2, which
is characteristically over-expressed in CLL, promoting survival of leukemia cells [31].
Indeed, there is a reciprocal relationship between expression of miR-15a and miR-16-1
and Bcl-2, and heterologous expression of these microRNAs suppresses Bcl-2 levels
6

[32]. Suppression is specifically mediated by complimentary binding sites for those
microRNAs in the 3’ untranslated region of the Bcl-2 transcript [32].

Further,

heterologous expression of miR-15a and miR-16-1 produces apoptosis in leukemia cell
lines [32]. Moreover, mouse models of spontaneous CLL possess a mutation in the 3’
untranslated region of miR-16-1, identical to mutations in patients with CLL, associated
with decreased expression of that microRNA [33]. Heterologous expression of miR-161 in CLL cells derived from those mice alters the cell cycle, proliferation and apoptosis
of these tumor cells [33].
The microRNA let-7, a phylogenetically conserved gene product that regulates the
transition of cells from proliferation to differentiation in invertebrates [34], also serves as
a tumor suppressor [27]. There are twelve let-7 homologs in humans forming eight
distinct clusters of which four are localized to chromosomal regions lost in many
malignancies [35].

In that context, downregulation of let-7 family members in lung

cancer is associated with poor prognosis [22]. A role for these microRNAs in growth
regulation and the expression of the tumorigenic phenotype is highlighted by the ability
of heterologous let-7 expression in lung cancer cells in vitro to inhibit colony formation
[36].

Key downstream targets for let-7 include the human Ras family of proteins,

oncogenes that are commonly mutated in many human tumors [23]. Indeed, KRas and
NRas expression in human cells is regulated by let-7 family members [27]. Moreover,
loss of let-7 expression in human tumors correlates with over-expression of Ras
proteins [23].
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MicroRNA Oncogenes (Fig. 2, Table 1)
The miR-17 cluster comprises a group of six miRNAs (miR-17–5p, miR-18a, miR-19a,
miR-20a, miR-19b-1 and miR-92) at 13q31–32, a chromosomal region amplified in large
B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and primary cutaneous Bcell lymphoma [37]. Consistent with their functions as oncogenes, over-expression of
this microRNA cluster is associated with amplification of the 13q31–32 genomic region
in lymphoma cells in vitro [37, 38]. These miRNAs are over-expressed in many types of
tumors, including lymphoma, colon, lung, breast, pancreas and prostate [17, 38, 39].
Interestingly, expression of the miR-17 cluster is induced by c-Myc, an oncogene overexpressed in many tumors. Heterologous expression of c-Myc up-regulates expression
of the miR-17 cluster, mediated by direct binding of that transcription factor to the
chromosomal region harboring those microRNAs [40].

In turn, the miR-17 cluster

appears to regulate several downstream oncogene targets. Thus, miR-19a and miR19b may regulate phosphatase and tensin homolog (PTEN), a tumor suppressor with a
broad

mechanistic

role

in

human

tumorigenesis,

through

interactions

with

complimentary sites in the 3’ untranslated region of this transcript [41]. Similarly, miR20a may reduce the expression of transforming growth factor (TGF)-β receptor II
(TGFBR2), a tumor suppressor frequently mutated in cancer cells which regulates the
cell cycle, imposing growth inhibition [17]. The best characterized target of the miR-17
cluster is the E2F1 transcription factor whose expression is regulated by miR-17–5p and
miR-20a [42].

In turn, E2F1 regulates cell cycle progression by inducing genes

mediating DNA replication and cell cycle control [43]. Beyond the regulation of key
targets contributing to transformation, the miR-17 cluster directly induces the
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tumorigenic phenotype.

Heterologous expression of the miR-17 cluster increased

proliferation in lung cancer cells in vitro [39]. Moreover, components of this cluster
accelerate the process of lymphomagenesis in mice [44].

The microRNA miR-21 is over-expressed in many solid tumors including breast, colon,
lung, prostate, stomach, and endocrine pancreas tumors, glioblastomas, and uterine
leiomyomas [17, 45-47]. This microRNA is encoded at chromosome 17q23.2, a genetic
locus which is frequently amplified in many tumors. The tumorigenic effects of miR-21
are mediated, in part, by targeting a number of mediators in critical cell survival
pathways. Thus, in glioblastoma cells in vitro miR-21 modulates the expression of the
common tumor suppressor PTEN, a central regulator of cell growth, proliferation, and
survival mediated by the PI3 kinase-Akt pathway [48]. Also, miR-21 regulates breast
cancer cell growth by reciprocally regulating apoptosis and proliferation, in part
reflecting regulation of the anti-apoptotic protein Bcl-2 [49]. Moreover, miR-21 controls
expression of the tumor suppressor tropomyosin 1 whose over-expression in breast
cancer cells suppresses anchorage-independent growth [50].

Beyond signaling

analyses, elimination of miR-21 expression in glioblastoma cells induces caspasedependent apoptosis, underscoring the importance of this microRNA in mediating the
survival phenotype [51]. Similarly, antisense oligonucleotides to miR-21 suppressed the
growth of breast cancer cells in vitro and in xenografts in mice [48].

MicroRNAs as biomarkers in cancer
Their fundamental role in development and differentiation, and their pervasive
corruption in lineage-dependent mechanisms underlying tumorigenesis suggest that
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microRNAs may be a particularly rich source of diagnostic, prognostic and predictive
information as biomarkers in cancer [8, 26, 52]. Differential expression of microRNAs
compared to their normal adjacent tissue counterparts is a characteristic of every type
of tumor examined to date [8, 52], a feature that could be particularly useful in
diagnosing incident cancers in otherwise normal tissues.

Indeed, this approach

discriminates normal and neoplastic tissues in various cancer types, including CLL,
breast cancer, glioblastoma, thyroid papillary carcinoma, hepatocellular carcinoma, lung
cancer, colon cancer and endocrine pancreatic tumors [8, 17-22, 26, 45, 52-54].
Similarly, microRNA expression profiles provide a powerful source of molecular
taxonomic information, with an accuracy for classifying tumors according to their
developmental lineage and differentiation state that surpasses mRNA expression
profiling [16, 17].

These observations suggest the utility of microRNA expression

profiling for identifying metastatic tumors of unknown origin, which represent ~5% of all
malignancies worldwide [16, 17, 52]. Also, differential microRNA expression patterns
are associated with disease prognosis [8, 52].

Specific patterns of microRNA

expression identified patients with pancreatic cancer who survived >24 months,
compared to those who survived <24 months [53].

In addition, the expression of

specific microRNAs predicted overall poor survival in patients with pancreatic cancer
[53]. Similarly, over-expression of specific microRNAs was an independent prognostic
variable associated with advanced disease stage and decreased survival in patients
with colon cancer [54].

Beyond diagnosis and prognosis, microRNA expression

patterns predict responses to therapy, and over-expression of oncogenic microRNAs
was associated with improved survival following adjuvant chemotherapy in patients with
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colon cancer [54].

These observations highlight the potential of microRNAs as

biomarkers for diagnosis, taxonomic classification, prognosis, risk stratification, and
prediction of therapeutic responses in patients with cancer.
Corruption of microRNA expression in cancer
The genetic basis of cancer, in part, reflects chromosomal rearrangements
encompassing translocations, deletions, amplifications, and exogenous episomal
integrations which alter gene expression.

The essential role of microRNAs in

tumorigenesis predicts coincidence between the location of their encoding genes and
those cancer-associated chromosomal regions. Indeed, more than half of microRNA
genes are located in cancer-associated genomic regions in a wide array of tumors
including lung, breast, ovarian, colon, gastric, liver, leukemia, and lymphoma [28, 35].
Conversely, chromosomal regions harboring microRNAs are sites of frequent genomic
alterations involved in cancer [28, 55].

Additionally, the impact of chromosomal

remodeling on gene copy number directly translates to altered microRNA expression
[19, 28, 55]. Beyond structural reorganization, epigenetic remodeling of chromosomal
regions harboring microRNA loci contributes to transformation, and tumor-suppressing
microRNAs silenced by CpG island hypermethylation result in dysregulation of essential
proteins accelerating the cell cycle, including cyclin D and retinoblastoma [56, 57].
Moreover, alterations in the machinery responsible for processing microRNA contributes
to tumorigenesis, and impairment of Dicer enhances lung tumor development in
experimental mouse models and is associated with poor prognosis in patients with lung
cancer [58-60].
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Therapeutic targeting of microRNAs

The causal role of microRNAs in molecular mechanisms underlying transformation and
the contribution of specific microRNA species to lineage-dependent tumorigenesis
suggest that these molecules could serve as therapeutic targets to prevent and treat
cancer [61]. In the context of established therapeutic paradigms in medical oncology,
individualized therapy with microRNAs could re-establish the expression of silenced
microRNA tumor suppressors, while antisense oligonucleotides could silence overexpressed oncogenic microRNAs [8, 28, 52, 61]. Indeed, antisense oligonucleotides
targeted to microRNA sequences (AMOs) with modified RNA backbone chemistry
resistant to nuclease degradation irreversibly eliminates over-expression of oncogenic
microRNAs [61]. Similarly, locked nucleic acid analogs resist degradation and stabilize
the microRNA target-antisense duplex required for silencing [62].

Moreover, single

stranded RNA molecules complimentary to oncogenic microRNAs, termed antagomirs,
silence microRNA expression in mouse models in vivo [63]. The specificity of targeting
inherent in nucleic acid base complimentarity coupled with their mechanistic role in
neoplastic transformation make microRNAs attractive therapeutic targets for future
translation.

Summary
MicroRNAs represent one fundamental element of the integrated regulation of gene
expression underlying nuclear-cytoplasmic communication.

Disruption of these

regulatory components in processes underlying tumor initiation and promotion
contributes to the genetic basis of neoplasia.
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Beyond molecular mechanisms

underlying pathophysiology that constitute therapeutic targets, unique patterns of
microRNA expression characterizing lineage dependent tumorigenesis offer unique
opportunities to develop biomarkers for diagnostic, prognostic, and predictive
management of cancer.

These novel discoveries are positioned to launch a

transformative continuum linking innovation to patient management. Advancement of
these novel paradigm-shifting concepts into patient application will proceed through
development and regulatory approval to establish the evidence basis for integration of
microRNA-based diagnostics and therapeutics into clinical practice.
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Table 1. MicroRNAs in tumorigenesis

MicroRNA

Gene

Tumor

Gene

Locus

Types

Targets

Ref

13q14

CLL, prostate, mantle cell

BCL-2

28-32

RAS

22, 23, 26,

Suppressors
mir-15a, 16-1

lymphoma, multiple
myeloma
let-7

8 clusters

lung, gastric

34, 35
Oncogenes
mir-17 cluster

13q31-32

B-CLL, follicular
lymphoma, mantle cell

PTEN

17, 36-38,

TGFβ RII

40-43

lymphoma, cutaneous B
E2F1
cell lymphoma, colon,
lung, breast, pancreas,
prostate
mir-21

17q23.2

breast, colon, lung,
prostate, gastric,

PTEN
BCL-2

endocrine pancreas,
Tropomyosin I
glioblastomas,
leiomyomas
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17, 44-50,
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FIGURE LEGENDS
Figure 1. MicroRNA generation and gene regulation [9]. Mature microRNAs of
about 22 nucleotides originate from primary microRNA (pri-microRNA) transcripts.
Nuclear pri-microRNAs of hundreds to thousands of base pairs are converted into stemloop precursors (pre-microRNA) of about 70 nucleotides by Drosha, an RNase III
endonuclease, and Pasha, a homologue of the human DiGeorge syndrome critical
region gene 8 (DGCR8). Pre-microRNAs undergo cytoplasmic translocation mediated
by exportin 5 in conjunction with Ran-GTP and subsequently processed into RNA
duplexes of about 22 nucleotides by Dicer, an RNase III enzyme, and Loqacious (Loqs),
a double-stranded RNA-binding–domain protein that is a homologue of the HIV
transactivating response RNA-binding protein (TRBP).

The functional strand of the

microRNA duplex guides the RNA-induced silencing complex (RISC) to the mRNA
target for translational repression or degradation.
Figure 2.

MicroRNA oncogenes and tumor suppressors [26].

a. Normally,

microRNA (miRNA) binding to target mRNA represses gene expression by blocking
protein translation or inducing mRNA degradation, contributing to homeostasis of
growth, proliferation, differentiation and apoptosis. b. Reduced miRNA levels, reflecting
defects at any stage of mirRNA biogenesis (indicated by question marks), produce
inappropriate expression of target oncoproteins (purple squares). The resulting defects
in homeostasis increase proliferation, invasiveness or angiogenesis or decrease levels
of apoptosis or differentiation, potentiating tumor formation.

c. Conversely,

overexpression of an oncogenic miRNA eliminates the expression of tumor-suppressor
genes (pink), leading to cancer progression. Increased levels of mature miRNA could

24

reflect amplification of the miRNA gene, a constitutively active promoter, increased
efficiency in miRNA processing or increased stability of the miRNA (indicated by
question marks). ORF, open reading frame.
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